# Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects

> **NCT02273544** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Asasantin ER (new formulation - low)
- **DRUG:** Asasantin ER (new formulation - medium)
- **DRUG:** Asasantin ER (new formulation - high)
- **DRUG:** Asasantin ER - commercial formulation

## Key facts

- **NCT ID:** NCT02273544
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-09
- **Primary completion:** 2002-10
- **Final completion:** —
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02273544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02273544, "Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02273544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*